A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension

BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has a well-characterized efficacy and safety profile in patients with hypertension. AZL-M is approved for use in over 40 countries globally; however, it is not yet approved in China. Therefore, a phase 3 registration study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiahui, Du, Xin, Lv, Qiang, Li, Zhanquan, Zheng, Zeqi, Xia, Yong, Tang, Chengchun, Yao, Zhuhua, Zhang, Jun, Long, Mingzhi, Hisada, Michie, Wu, Jingtao, Zhou, Wei, Ma, Changsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505320/
https://www.ncbi.nlm.nih.gov/pubmed/32769878
http://dx.doi.org/10.1097/MD.0000000000021465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505320/
https://www.ncbi.nlm.nih.gov/pubmed/32769878
http://dx.doi.org/10.1097/MD.0000000000021465

Ejemplares similares